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ARTICLE
A receptor for the complement regulator factor H
increases transmission of trypanosomes
to tsetse flies
Olivia J.S. Macleod 1, Jean-Mathieu Bart 2, Paula MacGregor 1, Lori Peacock3, Nicholas J. Savill 4,
Svenja Hester5, Sophie Ravel2, Jack D. Sunter 6, Camilla Trevor1,7, Steven Rust7, Tristan J. Vaughan7,
Ralph Minter 7, Shabaz Mohammed 5, Wendy Gibson3, Martin C. Taylor 8, Matthew K. Higgins 5✉ &
Mark Carrington 1✉
Persistent pathogens have evolved to avoid elimination by the mammalian immune system
including mechanisms to evade complement. Infections with African trypanosomes can
persist for years and cause human and animal disease throughout sub-Saharan Africa. It is
not known how trypanosomes limit the action of the alternative complement pathway. Here
we identify an African trypanosome receptor for mammalian factor H, a negative regulator of
the alternative pathway. Structural studies show how the receptor binds ligand, leaving
inhibitory domains of factor H free to inactivate complement C3b deposited on the trypa-
nosome surface. Receptor expression is highest in developmental stages transmitted to the
tsetse fly vector and those exposed to blood meals in the tsetse gut. Receptor gene deletion
reduced tsetse infection, identifying this receptor as a virulence factor for transmission. This
demonstrates how a pathogen evolved a molecular mechanism to increase transmission to an
insect vector by exploitation of a mammalian complement regulator.
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The mammalian complement system comprises abundantplasma proteins that initiate and propagate processes onpathogen surfaces resulting in their elimination. The
complement cascade is highly conserved across mammals and has
three arms: (i) the classical pathway triggered by specific binding
of antibodies or complement components to foreign antigens, (ii)
the lectin pathway initiated by binding of lectins to foreign oli-
gosaccharides, and (iii) the alterative pathway initiated by spon-
taneous and constitutive deposition of C3b onto a cell surface1–3.
All pathways trigger a response that can result in opsonization for
phagocytosis and/or the formation of a membrane attack com-
plex (MAC) that kills pathogens by compromising the integrity of
the plasma membrane.
Complement activation is limited on self-cells by a number of
negative regulators. For the alternative pathway, self-cells are
protected by complement factor H (FH), which binds to com-
ponents of the negatively charged glycocalyx4. FH blocks the
complement cascade by accelerating the decay of C3 convertase
(C3bBb), thus reducing C3b production, and by acting as a co-
factor for factor I, which cleaves and inactivates C3b4. FH is
composed of 20 tandem complement control protein (CCP)
domains with 6, 7 and 20 binding self-cell-negative surface
markers, whereas 1–4 and 19 bind C3b5–8.
FH recruitment by diverse pathogens has been shown to be an
effective strategy to inactivate complement in the host, but the
molecular basis has only been characterized for three bacteria:
Streptococcus pneumoniae, Borrelia burgdorferi and Neisseria
meningitidis9–12. These recruit FH by mimicry of mammalian
host interactions with FH or by increasing activity of FH. The
causal agent of malaria, Plasmodium falciparum, recruits FH at
three points in its developmental cycle, but molecular mechan-
isms have not yet been determined13–15.
In this work, we describe the identification and characteriza-
tion of a Trypanosoma brucei FH receptor (FHR). T. brucei is an
extracellular protozoan pathogen that causes human and animal
trypanosomiasis and is transmitted by tsetse flies16,17. T. brucei
has a complex life cycle with a series of developmental forms,
each having evolved a specialized cell surface to counteract host
defences in the relevant niche18,19. Although reported cases of the
human disease have diminished in the last decade, the animal
disease acts both as a reservoir of human infective trypano-
somes20 and continues to reduce livestock production, repre-
senting one of the largest constraints on livestock productivity by
pastoralists21.
The mechanisms by which T. brucei counteracts the mam-
malian adaptive immune response are well-characterized: anti-
genic variation at the population level and rapid clearance of
surface-bound immunoglobulin at the individual cell level22–24.
In addition, the pathways that inactivate trypanolytic factors, a
specialized form of innate immunity unique to humans and a few
other primates, have been characterized25,26. However, although
T. brucei activates the alternative complement pathway, it is not
known how progression to the MAC is prevented27–29. Here we
identify a trypanosome receptor that binds mammalian FH and
understand the molecular basis for the interaction, revealing how
a parasite exploits a mammalian protein to increase transmission
to an insect vector, a strategy that is likely to have evolved
independently many times in pathogens.
Results
Identification of a T. brucei FHR. Only two African trypano-
some receptors for host macromolecules have been functionally
characterized: the transferrin receptor and the haptoglobin hae-
moglobin receptor30,31. This work started with an assumption
that the interactions between trypanosomes and their hosts are
likely to be more extensive. A screen of the T. brucei genome was
performed to identify putative receptors based on one or both of
two criteria: first, a prediction that the structure contained a
three-helical bundle core, common in other characterized trypa-
nosome surface proteins32 and, second, that a cell surface loca-
lization was likely. The outcome was a list of 13 genes/gene
families (Supplementary Table 1).
One of these, Tb927.5.4020, encodes a polypeptide of 227
residues including predicted N-terminal signal and C-terminal
glycosylphosphatidylinositol (GPI)-anchor addition sequences.
The predicted mature polypeptide was expressed as a glutathione-
S-transferase (GST) fusion protein, immobilized on glutathione
beads, and used to precipitate any potential ligand from bovine
serum. The most abundant polypeptide was 145 kDa and was
identified as complement FH by mass spectrometry (MS) (Fig. 1a
and Supplementary Fig. 1a). The interaction was confirmed using
surface plasmon resonance (SPR). The putative receptor was
produced with a single biotinylation site near the C terminus and
was immobilized on a streptavidin chip. It bound bovine FH,
either purified from serum or as a recombinant protein, with a KD
value of 153 nM and 114 nM, respectively (Fig. 1b and
Supplementary Fig. 1b-f). FH is a highly abundant protein, with
concentrations ranging from 1.6 to 4.9 μM in normal human
adult serum33 and is similarly abundant in bovine serum34. This
concentration would enable near-to-complete saturation of the
receptor at the measured affinity. Together, these experiments
identify Tb927.5.4020 as a T. brucei FHR.
FHR membrane-distal region interacts with FH domain 5.
Next, the interaction interface between FHR and FH was char-
acterized. The binding site on FHR was investigated by identi-
fying conserved residues in the closest homologues to FHR in the
related species Trypanosoma congolense and Trypanosoma suis.
An alignment of these sequences highlighted a single region close
to the mature N terminus with most residues identical in all three
(Supplementary Fig. 1g). The conserved residues were tested by
mutagenesis of FHR followed by pulldowns from serum to assess
the effect of mutations on FH binding (Supplementary Fig. 1h).
FH was detected in pulldowns with FHR wild type (WT) and
mutant 1 (K46A, R47A), but was not detected with mutant 2
(E31A, Q34A) and mutant 3 (E31A, Q34A, K46A, R47A) (Sup-
plementary Fig. 1i). Circular dichroism (CD) spectroscopy was
used to confirm that the changes made in mutants 2 and 3 had
not substantially altered the structure at the temperatures at
which experiments were performed (Supplementary Fig. 2a-d).
Therefore, mutants 2 and 3 disrupted FH binding and were used
for further analysis.
A chemical cross-linking analysis was performed to identify
which part of FH bound FHR. FHR WT or non-binding mutant 3
were both biotinylated at the C terminus and mixed with FH and
a concentration range of either H12 or D12 disuccinimidyl
suberate (DSS) (Fig. 1c, d and Supplementary Fig. 2e, f). Specific
cross-linking was demonstrated by the presence of high-
molecular-weight biotinylated polypeptides in the reaction
containing the WT but not with mutant 3 (Fig. 1c, d and
Supplementary Fig. 2e, f). Cross-linked residues were identified
by MS of tryptic peptides. The most abundant cross-link by far
was between residue 283 in domain 5 of FH and residue 24 near
the membrane-distal N terminus of FHR (Supplementary Fig. 2g).
Other less abundant cross-links from FHR to FH domains 8 and
20 were also detected (Supplementary Fig. 2g).
These findings were used to guide the selection of FH domains,
expressed as single or tri-domains, for the investigation of FHR
binding specificity and kinetics (Fig. 2 and Supplementary
Fig. 3a-c). The highest affinity interaction, with a similar KD to
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full-length FH, was between FHR and FH domains 4-5-6 with a
KD of 167 nM and the KD for binding to domain 5 alone was 562
nM (Supplementary Fig. 3b, c). Binding of FHR to domains 7-8-9
and 18-19-20 were too weak to allow calculation of KD values
from the data obtained. Therefore, the N-terminal region of FHR
interacts primarily with FH domain 5.
FHR holds FH in a position conducive to C3b inactivation. The
structure of the FHR bound to FH domain 5 was determined by
X-ray crystallography (Fig. 3, Supplementary Fig. 3d-h and
Tables 2 and 3). The ordered part of the FHR structure observed
in the crystal starts at the mature N terminus (residue 25) and
ends 14 residues before the predicted mature C terminus and GPI
anchor (residue 237). FHR is an elongated three-helical bundle of
~90 Å similar to other trypanosome receptors32,35, but has
evolved a binding pocket for FH domain 5 through spreading
apart of the membrane-distal ends of the long second and third
helices (Fig. 3 and Supplementary Table 3). Domain 5 has a CCP
fold as expected36,37, with its N terminus pointing away from the
plasma membrane (Fig. 3a). Two copies of FHR and two of FH
domain 5 were present in the asymmetric unit of the crystal
(Supplementary Fig. 3f, g) with each receptor contacting both
copies of domain 5. Mutant 2 FHR (Supplementary Fig. 1h)
resolved which interaction was representative of the physiological
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Fig. 1 Identification of the T. brucei FHR and its interaction interface with FH. a SDS-PAGE analysis of pulldowns from bovine serum were performed with
GST or GST-Tb927.5.4020 immobilized on beads in five replicates or with a phosphate buffered saline (PBS) control. b SPR-binding data for C-terminally
biotinylated FHR (450 RU) bound to a streptavidin chip and twofold dilutions of FH purified from bovine serum (1 μM highest concentration). Data shown
are representative of three repeats. c SDS-PAGE analysis of cross-linking experiment using D12 disuccimidyl suberate (DSS) to probe the interaction
between FHR and FH. FHR and mutant 3 were biotinylated at the C terminus and incubated with FH prior to the addition of the cross-linker in a dilution
series as shown. d Western blotting of samples in c, probed with streptavidin peroxidase. Source data are provided as a Source Data file.
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Fig. 2 FHR binds FH domain 5. Schematic of the 20 domains of bovine FH showing the domains that were assessed for binding to FHR with the SPR-
binding data for each shown below. C-terminally biotinylated FHR (400 RU) was bound to a streptavidin chip and twofold dilutions of FH domains 4-5-6
(1.5 μM highest concentration), 7-8-9 (30 μM highest concentration), 18-19-20 (40 μM highest concentration), and domain 5 alone (5 μM highest
concentration) were analysed. Source data are provided as a Source Data file.
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complex and which was due to crystal packing. That is, mutant 2
contained mutations E31A and Q34A within one of the possible
interfaces; these alterations disrupted the receptor-ligand inter-
action by pulldown (Supplementary Fig. 1i) and also by SPR
analysis (Supplementary Fig. 3d, e), thus confirming that the
interaction is mediated by the binding site containing these
residues shown in Fig. 3.
The single predicted N-linked glycosylation site in FHR is
located at the extreme membrane-distal tip of the molecule
(Supplementary Fig. 3i) and in this position the oligosaccharide
could potentially reduce antibody accessibility of FHR molecules
embedded in the trypanosome surface coat without interfering
with FH binding.
To understand how the interaction might affect complement
function, we produced a model for the FHR-FH-C3b complex
(Fig. 4). This model used the known structures of C3b in complex
with FH domains 1–4 linked to 19-20 (PDB 5O35)38 and FH
domains 1–5, which show the domain 4-5 boundary to be highly
flexible (PDB 2QFG)37 (Supplementary Fig. 3j). In the model of
the FHR-FH-C3b complex, domains 1–4 of FH remain free in the
receptor-bound form to access and bind C3b deposited on the
periphery of surface coat and so inhibit the complement cascade.
FHR was identified and characterized using bovine serum and
FH. As African trypanosomes can infect a wide range of
mammals, we also tested whether FH from different species
could bind FHR. First, the degree of conservation of the 18
interactions between FHR and bovine FH domain 5 (Supple-
mentary Table 3) was assessed, and this varied from 18
potentially conserved interactions in sheep, 17 in goat and 9–15
in pig, horse, rabbit, rat, mouse and human (Supplementary
Table 4). Next, interactions were tested directly using the
pulldown approach that identified bovine FH (Supplementary
Fig. 4a, b). FHR clearly pulled down FH from sheep, goat and pig
sera, but FH from horse, rabbit, rodent and human was not
readily observed, suggesting weaker interaction with FHR. The
likelihood of pulldown broadly followed the number of conserved
interacting residues.
As pulldown outcomes are very sensitive to off rates, FH from
two species with low numbers of conserved interactions, human
and mouse, were made as domains 4-5-6 recombinant proteins
and tested for interaction with FHR using SPR (Supplementary
Fig. 4c-e). Both mouse and human proteins bound to WT FHR
but not mutant 2 FHR, albeit with weaker affinities of KD= 12
μM for mouse and KD= 8.7 μM for human, compared with that
of bovine, KD= 0.167 μM. These affinities are in the same range
as the concentration of FH in serum, suggesting that a fraction of
the receptors will be FH bound in vivo. A further SPR experiment
was performed using immobilized FHR and mouse plasma from
WT and FH-null mice (Cfh−/−) (Supplementary Fig. 4f). There
was a clear binding response of 200 RU from the WT serum but
not the FH-null plasma. Together, these observations indicate
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Fig. 3 The structure of FHR bound to FH domain 5. a Two views of FHR (blue) bound to FH domain 5 (pink). The N and C termini of FHR and domain 5 are
indicated. The C terminus of FHR is plasma membrane proximal. b View of FHR (blue) bound to FH domain 5 (pink) viewed from the membrane-distal end.
c Surface representation of the FH-binding pocket in FHR (blue) with the FH domain 5 (pink).
C3b
FH 1–4
Flexible at domain
4–5 boundary
FHR
FH 5 Thioester
FH 6–18 cartoon
FH 19–20
Plasma membrane
Fig. 4 FHR holds FH in a position in which it can access surface-bound
C3b. A cartoon model for how the FHR (blue) could hold FH (pink) distal to
the plasma membrane, to interact with C3b (yellow). The model combines
the FHR:FH domain 5 structure with previously determined structures PDB
5O35 and 2QFG.
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that FHR interacts specifically with mouse FH. We therefore
continued to characterize the cellular behaviour of FHR and
assess its function in tsetse flies and in the standard mouse model
of infection.
FHR is expressed in tsetse-transmissible and gut forms. In the
mammalian host, T. brucei exists as proliferating slender and
quiescent stumpy bloodstream forms (BSFs). Slender BSFs dif-
ferentiate to stumpy BSFs in response to a density-dependent
quorum-sensing mechanism and both stages are continually
exposed to complement39,40. Only the stumpy BSFs readily infect
tsetse flies39,40 where, in the midgut, they differentiate first into
procyclic forms (PCFs) and subsequently mesocyclic forms as
they migrate towards the proventriculus41. The midgut and
proventriculus are exposed to fresh complement in the immediate
aftermath of a blood meal. Mesocyclic forms in the proventriculus
differentiate to epimastigote forms, which migrate to the salivary
glands away from direct contact with blood and differentiate
further to forms able to re-infect the mammalian host.
Whole-cell lysates from cultured slender and induced stumpy
BSFs and PCFs were used to determine FHR expression levels by
semi-quantitative western blotting. First, the specificity of FHR
antiserum was shown using a set of lysates from cells with both
alleles of FHR deleted (FHR−/−) as negative controls (Fig. 5a and
Supplementary Fig. 5a, b). FHR expression was detected in
induced stumpy BSFs42,43 and increased further in PCFs with an
estimated ~200,000 copies/cell (Fig. 5a and Supplementary Fig. 5c,
d). FHR was below the level of detection in slender BSFs (< ~200
copies/cell) (Fig. 5a and Supplementary Fig. 5c, d). The increase
in expression on differentiation from slender to induced stumpy
BSFs was confirmed using cell lysate of stumpy BSFs isolated
from a mouse infection (Fig. 5a). Thus, expression of FHR
increases during differentiation from slender to stumpy BSFs and
further in PCFs where it is an abundant protein.
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Fig. 5 FHR is upregulated on the cell surface of forms that are adapted to life in blood ingested by the tsetse fly. a Western blot analysis probed with
FHR antiserum (αFHR) of whole-cell lysates from FHR+/+ and FHR−/− slender BSFs, induced stumpy BSFs, and PCFs in culture and from FHR+/+ stumpy
BSFs from a mouse infection. Anti-PFR (αPFR) was used as a loading control. b, c Live-cell-binding assay of 100 nM fluorescent b bovine FH or c FHR-moAb
to PCFs in culture. After 2 h, cells were fixed in culture and visualized. Scale bar, 10 μm. d Immunofluorescence analysis of localization of FHR during the
majority of the T. brucei life cycle. Cells were collected, fixed and then probed with FHR antiserum. Scale bar, 10 μm. DNA, Hoechst staining of the nuclear
and kinetoplastid DNA. Cells positioned with the posterior towards the top right corner. Bars beneath the microscope images represent where complement
is present during the life cycle (yellow gradient) and FHR expression (blue gradient). Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15125-y ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1326 | https://doi.org/10.1038/s41467-020-15125-y | www.nature.com/naturecommunications 5
FHR binds both FH and a monoclonal antibody in live cells. To
investigate FHR function and accessibility to ligand on live cells,
fluorescently labelled FH or FHR monoclonal antibody (moAb)
were each added to a culture of PCFs for 2 h and any binding
visualized by microscopy (Fig. 5b, c). Ligands were added directly
to growing cells, so labelled FH added would be diluted by FH in
the serum in the culture medium. Nevertheless, in FHR+/+ cells,
signal for fluorescently labelled FH was observed both on the cell
surface and within cells indicating that the FHR binds FH on the
cell surface and may mediate some endocytosis (Fig. 5b). FHR+/+
cells also bound the FHR-moAb over the entire cell surface, with
a fraction endocytosed (Fig. 5c). No binding of either ligand was
observed to FHR−/− cells (Fig. 5b, c). These observations
demonstrate that FHR on the cell surface is accessible to large
ligands and supports the structural model of FHR-mediated
protection against complement killing.
FHR is on the cell surface of forms exposed to blood. The
subcellular localization of FHR was investigated by immuno-
fluorescence. First, FHR was distributed over the entire cell sur-
face of induced stumpy BSFs (Fig. 5d and Supplementary Fig. 6).
Second, as developmental forms in the tsetse fly are not readily
accessible in culture, trypanosomes from infected flies were used
to assess expression in the various developmental forms in the
gut. Flies were infected with PCFs of the parental FHR+/+
and FHR−/− clones in the absence of complement. All cell
lines established infections without significant difference between
FHR+/+ and FHR−/− clones (Supplementary Fig. 5e). At days 3
and 10 post infection, FHR was distributed over the cell surface of
FHR+/+ PCFs (Fig. 5d and Supplementary Fig. 7). By day 10 post
infection, cells had migrated to the proventriculus and differ-
entiated further44. Mesocyclic FHR+/+ cells expressed FHR over
the cell surface (Fig. 5d and Supplementary Fig. 8). However,
FHR was not detected in epimastigote forms from the proven-
triculus (Fig. 5d and Supplementary Fig. 8), which is the stage
that migrates to the salivary glands44. No signal was present
throughout for the FHR−/− control (Fig. 5d and Supplementary
Figs. 6–8). Therefore, expression of high levels of FHR is specific
to stumpy BSFs and developmental forms in the tsetse fly that are
exposed to mammalian blood. The cell surface localization in
these forms is again consistent with FHR facilitating inactivation
of complement at the trypanosome cell surface.
FHR−/− T. brucei are attenuated in mice. In all the experiments
described above, complement had been inactivated in culture
media and was absent in feeds of tsetse flies. The FHR−/− cell
lines were made by first deleting both alleles of the FHR gene in
cultured PCFs in the absence of complement (Supplementary
Fig. 5a, b). Two independent FHR−/− PCF clones and a parental
PCF FHR+/+ were used to infect tsetse flies, again in the absence
of active complement. Infection with all three trypanosome lines
progressed to the salivary glands and infected glands were used to
inoculate BALB/c mice. BSFs were recovered from all infected
mice, indicating growth of FHR−/− cells in the presence of mouse
alternative complement pathway. To test whether any alterations
in growth rate had been caused by the FHR gene deletion, one
BSF FHR+/+ and one BSF FHR−/− clone were adapted to growth
in culture. Both PCF and BSF FHR−/− cells had no growth rate
phenotype (Supplementary Fig. 5f, g). These were the PCF and
BSF cell lines used in the experiments above that characterized
FHR expression.
Next, any phenotype caused by deletion of the FHR in the
presence of mouse complement was tested using the standard
mouse model of infection. Groups of five immunosuppressed and
five untreated BALB/c mice were infected with BSF FHR+/+ or
one of the two independent FHR−/− clones, and blood
parasitaemia was measured over a time course. FHR−/− clones
were able to establish and maintain infections in all mice;
however, a mild attenuation in the parasitaemia was observed for
both FHR−/− clones (Fig. 6a, b and Supplementary Fig. 9a, b).
In both sets of infections, the first peak of parasitaemia for
FHR−/− clones declined before the parental FHR+/+ and the
total parasitaemia for both FHR−/− clones was lower at nearly
all time points in the chronic phase of infection after day 10
(Fig. 6a, b and Supplementary Fig. 9a, b).
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Fig. 6 The transmission of T. brucei FHR−/− cell lines to tsetse flies from
mice was significantly reduced compared with FHR+/+. a, b Mean mouse
blood parasitaemia of parental FHR+/+ and two independent FHR−/−
clones, with error bars representing the SEM. a Five immunosuppressed
BALB/c mice were infected with each cell line and monitored from days
3–14 post infection. b Five immunocompetent BALB/c mice were infected
with each cell line and monitored from days 2–24 post infection. c Tsetse
flies were fed on infected mice and transmission of the infection was
evaluated by the dissection of >100 midguts per cell line on days 6–16 post
infection. The total number is derived from seven replicates per cell line.
The number of infected midguts over the total dissected midguts is plotted,
whereby 31/114 were infected for FHR+/+, 12/119 for FHR−/− clone 1, and
11/106 for FHR−/− clone 2. The observed difference between the FHR+/+
and each of the FHR−/− clones was significant (P < 0.002 for each cell line
by χ2-test). Source data are provided as a Source Data file.
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The parasitaemia in animals describes the total number of both
slender and stumpy BSFs, and is influenced by the proliferation
of slender BSFs, the lifespan of each life stage and the clearance
of parasites by the host immune system. The upregulation of
expression of FHR in stumpy BSFs (Fig. 5a, d and Supplementary
Fig. 6) suggests that FHR deletion would likely cause attenuation
and decreased viability of stumpy forms. A functional role for
FHR in stumpy BSFs could explain both the more rapid decline in
the first peak of parasitaemia and the reduced levels after the
infection has established. This early decline in the first peak of
parasitaemia was reminiscent of infections previously observed
during mouse infections with akinetoplastic T. brucei caused by a
reduction in stumpy BSF lifespan45. Using a similar mathematical
model for in-host dynamics during trypanosome infections45,46, a
prediction from an analysis of the measured parasitaemia
indicated that the lifespan of FHR−/− stumpy forms was reduced
from 27 to 7 h, but this was not tested directly, as FHR is not
necessary for infectivity (Supplementary Figs. 9c, d and 10, and
Supplementary Data 1).
FHR−/− T. brucei have reduced transmission to tsetse flies. To
test for the effect of FHR on transmission in the presence of
complement, tsetse flies were given a single feed on mice infected
with either FHR+/+ or FHR−/− trypanosomes in seven replicates,
in each case using mice with similar levels of parasitaemia. The
tsetse flies were then fed at 2-day intervals with whole sheep
blood through a feeding membrane. The flies were dissected
between 6 and 16 days after the feed on infected mice and the
midguts scored for the presence of trypanosomes. Both FHR−/−
clones had a significantly reduced ability to infect tsetse flies with
2.7-fold (clone 1, p < 0.001 by χ2-test) and 2.6-fold (clone 2, p <
0.002 by χ2-test) decreases compared with the FHR+/+ control
(Fig. 6c). These observations show that FHR acts as a virulence
factor for transmission to tsetse flies.
Discussion
How trypanosomes counteract the alternative complement
pathway has been little studied. Previously, it has been shown that
C3 convertase (C3bBb) can assemble on the surface of BSFs but
the complement cascade did not progress further and there was
no recruitment of complement proteins C5b-9 to form a MAC28.
Here we have identified and characterized FHR, a receptor that
binds FH in a manner that would enable FH to negatively reg-
ulate C3b and C3bBb preventing MAC formation. FHR was not
detected in proliferating slender BSFs but was upregulated in
quiescent stumpy BSFs, the developmental form adapted for
transmission to tsetse flies. It was further upregulated in the
developmental forms exposed to blood meals in the tsetse gut,
then becoming undetectable as the trypanosomes departed the
midgut for the salivary glands. This FHR expression pattern is
consistent with a role in transmission to and maintenance within
the tsetse fly, and indeed FHR−/− trypanosomes had reduced
transmission.
There are three steps necessary for successful transmission:
first, sufficient numbers of stumpy BSFs in a blood meal; second,
successful differentiation to PCFs; and third, survival and pro-
liferation of PCFs in the face of subsequent blood meals. Mod-
elling of the measured infection kinetics suggested that FHR−/−
stumpy BSFs do not survive as long as WT in mice. Reduced
survival may arise from differences in cell surface architecture
between slender and stumpy BSFs, resulting in a greater deposi-
tion of C3b on stumpy BSFs and thus increased susceptibility to
the alternative pathway that is mitigated by FHR expression. As
yet, no comprehensive comparison of slender and stumpy BSF
surfaces is available. Any reduced survival is unlikely to result
from an increased persistence of individual surface C3b molecules
as previous work demonstrated that there is more rapid inter-
nalization and clearance of surface-bound antibodies in stumpy
BSFs compared with slender BSFs22. Further, stumpy BSFs are
more resistant than slender BSFs to antibody-dependent lysis by
the classical complement pathway22,47. A reduced survival of
FHR−/− stumpy BSFs may contribute to reduced transmission.
The transition of BSFs to PCFs involves a total remodelling of
the cell surface and occurs in a blood meal18,48, and FHR may
contribute to protection of these differentiating cells. FHR
expression increases further in trypanosomes resident in the
tsetse gut. PCFs can be lysed by the alternative complement
pathway in vitro and knockdown of tsetse serpins, which inac-
tivates complement in a blood meal, reduced, but did not abolish,
the ability of cultured PCFs to directly establish infections
in vivo27,29. Expression of FHR in mesocyclic forms suggests that
continued protection is favoured during and in the immediate
aftermath of blood meals. The evidence here supports a model in
which FHR contributes toward protection against complement
but also acts in concert with tsetse fly serpins.
How are slender BSFs protected against the alternative pathway
of complement given the very low expression or the absence of
FHR? It is probable there are additional mechanisms of inacti-
vation and it is likely that the trypanosome expresses a set of
receptors/binding proteins for complement components, as found
in various microorganisms. Further, any mechanism evolved to
negate the alternative pathway is unlikely to depend on a single
molecule, as this would provide a ready route for a host to evolve
a countermeasure.
The structure of FHR is a further example of the three-helical
bundle family of trypanosome cell surface proteins32,35. This
structural fold clearly provides flexibility for the evolution of a
range of different binding specificities. In FHR, the ends of two
helices have splayed apart to form a binding pocket for domain 5
of FH. The fold is permissive for elongated receptors to access
ligands within the densely packed trypanosome cell surface coat.
The location of the FH-binding site is informative about the
mode of action; by binding FH domain 5 at a site distal to the
plasma membrane, FH domains 1–4 are located in the likely
location of deposited C3b at the periphery on the cell surface coat.
FHR binds with variable affinity to FH from different mam-
mals. T. brucei has a large host range and predominantly infects
livestock and wild game, whereas human infective isolates are
zoonotic20. The highest affinity of FHR was for FH from domestic
animals (cow, sheep, goat, pig) most closely related to the game
animals in sub-Saharan Africa that were the reservoir of T. brucei
prior to the development of agriculture. Mouse and human FH
bind with a lower affinity. Across all mammals tested, FHR-FH
interactions had KD values in the high nanomolar to low
micromolar range. As the concentration of FH in serum is in the
low micromolar range, FHR is expected to be largely occupied,
especially if there is additional avidity due to the formation of a
tripartite complex of surface-bound C3b-FH-FHR.
There is more than one way to catch FH and binding proteins
from a range of pathogens present a remarkable example of
convergent evolution. The trypanosome FHR structure and the
FH domain bound are different to each of the three structurally
characterized FH-binding proteins from bacteria. These interact
with FH domains 6–7 in N. meningitidis12, domain 9 in S.
pneumoniae10 or domains 19–20 in B. burgdorferi11. The binding
of these FHRs to domains 6–7 and 19–20 mimic self-surface
interactions and to domain 9 produces a high-affinity interaction
that enhances activity of FH for C3b in one strain9. Among other
eukaryotic pathogens, P. falciparum recruits FH in blood stage
schizonts and merozoites, and in emerging gametes following
transmission to the mosquito midgut. In merozoites, Pf92 binds
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FH through domains 5 and 20, and in gametes PfGAP40
binds FH through domains 5–7. The latter facilitates transmission
to the mosquito and protection from complement in the
midgut13–15. The structural mechanisms for the binding of FH
have not been reported and the Plasmodium proteins are also
unrelated to trypanosome FHR by sequence comparison.
Our findings represent a clear demonstration of how a
pathogen receptor for a mammalian complement regulator
enables it to act as a virulence factor for transmission to an insect
vector. They show how trypanosomes have evolved to exploit
mammalian FH and lead to a structural mechanism and mode of
action of this receptor, providing a deeper understanding of
pathogen anti-complement strategies.
Methods
Screen of genome for putative surface receptors. A screen was performed on all
T. brucei-annotated open reading frames (ORFs) from the TREU 927 reference
genome49 using the big-PI Predictor50. Each gene from this initial screen was
assessed manually for the presence of an N-terminal signal sequence, the absence of
a predicted transmembrane domain in the middle of the protein and a C-terminal
GPI-anchor signal peptide with similarity in sequence to a pattern established by
known GPI-anchored proteins (in T. brucei, Ttypanosoma cruzi, and Leishmania
major). In addition, structural homology predictions were performed using
FUGUE51 and Phyre252 servers.
GST fusion trypanosome proteins. For the first set of pulldown experiments,
DNA encoding amino acids 25–251 of the FHR was amplified from a pOPINF
vector (see below) already containing this sequence. Oligonucleotides 5′-GGA
TCCGGTTCTGGTAACGATAATCTTGAAGCCGAA-3′ and 5′-GTTAATCAC
AAACTGGTCTAGAAAGCTT-3′ were used and the PCR product cloned in
pGEM-T, sequenced, digested with BamHI and HindIII, and cloned into the
corresponding sites of pGEX-KG, encoding a fusion protein with a 5-residue linker
(GSGSG) between GST and FHR. In the second round of pulldown experiments
with FHR and mutants, the amplicon was produced from T. brucei Lister 427
genomic DNA encoding residues 25–249 of the FHR using primers 5′-CATAT
GGAAAATCTGTACTTCCAAGGCAACGATAATCTTGAAGCCGAATTG-3′
and 5′-GGATCCTTATTCATCTTCCTTATCTTCATCGG-3′. Product was cloned
as above, this time into a modified pGEX-KG vector, whereby the resulting fusion
protein had a longer linker sequence (GSSGGGG) and a Tobacco Etch Virus (TEV)
protease cut site between the GST tag and FHR. Mutants 1, 2 and 3 were generated
by PCR using the WT FHR vector as template and primers containing the desired
mutations. To generate mutant 1: 5′- TGTGAGGTGGCGAAACAACTGGCTGC
ACTTCCGCTGCTGATGGAAGAG-3′ and 5′-CTCTTCCATCAGCAGCGGAAG
TGCAGCCAGTTGTTTCGCCACCTCACA-3′, and mutant 2: 5′-AACGATAATC
TTGAAGCCGCATTGGAAGCGACGAAAGCACTATGTGAG-3′ and 5′-CTCAC
ATAGTGCTTTCGTCGCTTCCAATGCGGCTTCAAGATTATCGTT-3′ primers
were used. Mutant 3 was generated by performing PCR on a confirmed mutant 2
with mutant 1 primers.
GST fusion proteins were expressed in Escherichia coli BL21, incubated at 37 °C,
induced for 3 h with 0.02 % (w/v) isopropyl β-D-1-thiogalactopyranoside and
purified with glutathione-sepharose affinity chromatography. Purified proteins
were buffer exchanged into phosphate-buffered saline (PBS).
Pulldowns using GST fusion proteins. Glutathione-sepharose 4B (GE Healthcare,
140 μl slurry/pulldown) was incubated with GST-tagged protein (1 mg/pulldown)
for 30 min, washed with PBS and incubated with adult bovine, fetal bovine, sheep,
goat, pig, horse, rabbit, rat, mouse, human sera (Sigma-Aldrich, 1 ml/pulldown) or
a PBS control for 60 min. The beads were rapidly washed with 3× PBS washes in 5
min total. Bound protein was eluted using SDS-polyacrylamide gel electrophoresis
(PAGE) sample buffer and heating at 50 °C.
Protein electrophoresis and visualization. Protein samples were prepared and
analysed using by SDS-PAGE and standard methods. Western blotting used
Immobilon-P membrane (Millipore) and standard methods. Rabbit FHR anti-
serum was generated against recombinant FHR (Covalab) and used as primary
antibody (CUK-1457 1, 1:8000 dilution). A mouse moAb (L13D6, 1:100 dilution)
to a paraflagellar rod protein was used as loading control (kind gift of Keith Gull)53.
Donkey or goat anti-rabbit and donkey anti-mouse horseradish peroxidases (HRP;
1:5000 dilutions) were used as secondary antibody. Streptavidin HRP (strep POD)
was used at varying dilutions as specified.
MS for protein identification. Pulldown samples were fractionated by SDS-PAGE
(Criterion XT-PreCast Gel, 12 % Bis-Tris, Bio-Rad) and protein bands were
excised, trypsin-digested and run on an liquid chromatography-tandem MS (LC-
MS/MS) system by electrospray ionization-quadropole-time of flight (ESI-QUAD-
TOF) in the Advanced Proteomics Facility (University of Oxford) using standard
procedures. Results were searched against the UniProtKB/Swiss-Prot database and
analysed by Mascot.
Hexahistidine and AviTag fusion trypanosome proteins. For SPR, cross-linking
and CD analyses, synthetic genes were synthesized that were optimized for
expression in E. coli. After cloning into pET15b, proteins encoded a N-terminal
hexahistidine (6×his) tag followed by a TEV cleavage site, FHR/mutant 3 residues
25–249, a GSGSGSS linker and a C-terminal AviTag. To generate mutant 2,
mutagenesis was performed on the vector containing the WT FHR sequence with
the QuikChange II Site-Directed Mutagenesis Kit (Aligent) using primers 5′-AA
TGATAATCTGGAAGCAGCACTGGAAGCAACCAAAGCACTGTGTGAA-3′
and 5′-TTCACACAGTGCTTTGGTTGCTTCCAGTGCTGCTTCCAGATT
ATCATT-3′.
For crystallography, FHR residues 25–251 were cloned from TREU 927
genomic DNA into a pOPINF vector (Oxford Protein Production Facility)
containing an N-terminal 6×his tag and a PreScission cut site, which leaves an N-
terminal glycine–proline post cleavage. Proteins were expressed in E. coli BL21
(DE3) in the same manner as described for GST fusion proteins and purified with
nickel-nitrilotriacetic acid (Ni2+-NTA) affinity chromatography. Purified proteins
were buffer exchanged into PBS. His tags were removed by incubation for 2 h with
TEV protease at 37 °C or PreScission protease at room temperature54, which were
subsequently removed with another round of Ni2+-NTA affinity chromatography.
Further processing of proteins was performed as required by the assay and is
described in the following sections.
Cloning, expression and purification of mammalian proteins. Sequences
encoding bovine FH (Q28085, UnitProt) and various truncations were synthesized
after codon optimization for expression in Chinese hamster ovary (CHO) cells:
complete (residues 18–1236), domains 4-5-6 (residues 207–385), domains 7-8-9
(residues 385–564) and domains 18-19-20 (residues 1052–1236). Sequences con-
taining mouse domains 4-5-6 (P06909, UnitProt, residues 207–387) and human
(P08603, UnitProt, residues 207–387) were also synthesized in the same manner.
All of the above were cloned into a pDest12 vector for mammalian expression
driven by a cytomegalovirus promoter. The CD33 signal peptide was used for
protein secretion and tags were placed at either the N or C terminus based on the
composition of the protein. For example, tags were not placed at the C terminus of
proteins containing FH domain 20, as this is the native C terminus. The final
expression vector encoded the CD33 signal peptide, followed by either (1) an N-
terminal 10 × his tag, an AviTag, a GSGSGS linker before the ORF (for domains
18-19-20) and also a TEV site before the ORF (for full-length bovine FH), or (2)
the ORF, a C-terminal GSGSGS linker, AviTag and 10×his tag (for domains 4-5-6
and 7-8-9). Further truncations were generated by PCR of the vector containing
bovine FH. Domain 5 (residues 264–323) was amplified with primers 5′-GCTAG
CGGATCTGGCAGCGGTAGCGAGAACCTGTACTTTCAAGGCAGCGGCGAG
ATCACATGCGACCCTCC-3′ and 5′-GCTAGCTCATCACTTCCAGGCGCATC
TAGGC-3′ for N-terminal tags, a TEV site and an extra serine–glycine linker.
The expression plasmids were used to transfect G22 CHO cells, which were
grown in 500 ml serum-free CCM8 medium (SAFC). Cells were subsequently
cultured for 8 days and supplemented on days 1, 3 and 6 by the addition of 3.3% F9
and 0.2% F10 cell feed (AstraZeneca). Secreted recombinant protein was recovered
from the culture supernatant by Ni2+-NTA affinity chromatography. Purified
proteins were buffer exchanged into PBS and further processing of proteins was
performed as below.
Biotinylation. Biotinylation of proteins containing an AviTag was performed, by
mixing protein at 30 μM with 0.5 μM BirA, 5000 μM ATP and 300 μM biotin. They
were incubated at room temperature overnight, before desalting to remove excess
biotin. Biotinylation was assessed by western blotting using strep POD.
Purification of bovine FH from serum. Recombinant FHR (7 mg) was immobi-
lized onto 8 ml N-hydroxysuccinimide-activated agarose spin columns. The FHR-
agarose was incubated with adult bovine serum. Flow-through and subsequent
washes with PBS were discarded and bovine FH was eluted with 0.1 M glycine-HCl
pH 2.5. Elution fractions were immediately neutralized with 1M phosphate buffer
pH 8.5. Elution fractions were dialysed against PBS.
Surface plasmon resonance. Biacore T-100 and T-200 (GE Healthcare) were used
to perform SPR analyses of protein–protein interactions. All analyses were per-
formed at 20 °C in 10 mM HEPES, 150 mM sodium chloride, and 0.005% Tween-
20 pH 7.5. Biotinylated FHR or mutants were immobilized on a streptavidin-coated
chip (Series S Sensor Chip SA). Ligand was serially diluted twofold into running
buffer and flowed over the chip surface, followed by running buffer. Regeneration
used 0.1 M glycine-HCl pH 2.5. Binding responses were obtained by subtracting a
blank response from the FHR/mutant responses. A two-state reaction model
(bovine FH) or a 1 : 1 interaction model (bovine FH domains 4-5-6 and 5) were fit
to blank subtracted kinetic sensorgrams using the BIAevaluation software, enabling
the determination of the affinity (KD) and kinetics of the interaction (kon, koff).
For interactions with a fast dissociation rate (koff) (mouse and human FH
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domains 4-5-6), steady-state levels as a function of ligand concentration were
analysed to obtain KD only.
Mouse plasma for SPR. Cfh+/+ and Cfh−/− mouse plasma were obtained as a
kind gift from The Sanger Mouse Genetics Programme (Sanger MGP). For each
Cfh+/+ and Cfh−/− sample, plasma from three age-matched female mice were
pooled (full strain C57BL/6 N(25%) and C57BL/6NTac(75%)).
Chemical cross-linking and MS. Cross-linking experiments were performed with
DSS H12 and D12 (Creative Molecules). FHR/mutant 3 and purified native bovine
FH were incubated together for 30 min at room temperature in PBS or individually
with PBS as a control. All tubes contained the same molarities of components (10
μM FHR/mutant 3, 3.3 μM FH). A titration of cross-linker was added to aliquots of
the protein solutions for 20 min. Samples were analysed by SDS-PAGE and western
blotting. For MS analysis, biotinylated FHR/mutant 3 were incubated with bovine
FH. Half of the mixture was incubated with 125 μMH12 DSS and half with 125 μM
D12 DSS. The reaction was stopped using a final concentration of 10 mM
methylamine pH 8 and samples were treated with PNGase F under native con-
ditions. The sample containing FHR+ FH+D12 DSS was mixed in equal volume
with mutant 3+ FH+H12 DSS and the sample containing FHR+ FH+H12 DSS
was mixed in equal volume with mutant 3+ FH+D12 DSS. Samples were frac-
tionated by SDS-PAGE (4–12% Bis-Tris NuPAGE gel, Invitrogen) and high-
molecular-weight cross-linked proteins were excised.
Thiols were reduced with tris(2-carboxyethyl)phosphine and alkylated with
chloroacetamide before overnight digestion with Sequencing Grade Modified
Trypsin (Promega) at 37 °C. Peptides were separated on an EASY-nLC 1000
UHPLC system (Proxeon) and electrosprayed directly into a Q Exactive Hybrid
Quadrapole Orbitrap LC-MS/MS mass spectrometer. Peptides were trapped on a
C18 PepMap 100 pre-column (300 µm × 5mm, 100 Å) using 0.1% formic acid in
water at a pressure of 500 bar and then separated on an in-house packed analytical
column (75 µm × 50 cm packed with ReproSil-Pur 120 C18-AQ, 1.9 µm, 120 Å, Dr
Maisch GmbH) with a linear gradient (10–55% of 0.1% formic acid in acetonitrile
for 45 min, flow rate= 200 nL/min). Full-scan MS spectra were acquired in the
Orbitrap (scan range 350–2000 m/z, resolution 70,000, AGC target 36 ions,
maximum injection time 100 ms). After the MS scans, the ten most intense peaks
were selected for higher-energy collisional dissociation (HCD) fragmentation at
30% of normalized collision energy. HCD spectra were also acquired in the
Orbitrap (resolution 17500, AGC target 54 ions, maximum injection time 120 ms)
with first fixed mass at 100 m/z. Charge states 1+ and 2+ were excluded from
HCD fragmentation.
MS data were converted into mgf format using pParse and searched using the
pLink software55. The database contained the target proteins only. Search
parameters were as follows: maximum number of missed cleavages= 2, fixed
modification= carbamidomethyl-Cys, variable modification 1=Oxidation-Met,
variable modification 2=Glu to pyro-Glu. Data were initially filtered by E-value <
1.0−8. Cross-links were further filtered/inspected with specific emphasis on
fragmentation patterns.
CD and thermal melts. Far ultraviolet CD spectroscopy was performed on WT,
mutant 2 and mutant 3 FHR using a J-815 Spectropolarimeter (Jasco) and a Peltier
temperature control unit. Proteins were analysed at 0.2–0.25 mg/ml in 50 mM
sodium phosphate pH 7.5 with a 1 mm path cell between 190 and 260 nm at 20 °C.
For each protein, ten runs were acquired at a scanning speed of 50 nm/min with
the buffer baseline subtracted. For thermal melts, proteins were analysed at
0.05–0.09 mg/ml in 50 mM sodium phosphate pH 7.5 with a 1 mm path cell
between 190 and 250 nm at 0.5 °C increments from 20 °C to 96 °C.
Crystallography. His tags were removed from the FHR and domain 5 by Pre-
Scission and TEV proteases as detailed above, followed by Ni2+-NTA affinity
chromatography and dialysis into 20 mM Tris, 150 mM NaCl pH 8. After con-
centration (Amicon Ultra centrifugal filters, 10,000 or 3,000 Da molecular weight
cutoff), proteins were mixed in a 1 : 1.05 molar ratio with domain 5 in slight excess.
The mixture was purified using size-exclusion chromatography with a Superdex
200 16/60 column (GE Healthcare) into 10 mM Tris, 50 mM NaCl pH 8. Purified
complex was concentrated to 14 mg/ml and subjected to sitting drop vapour dif-
fusion crystallization. A mosquito LCP (TTP Labtech) was used to mix 100 nl of
complex with 100 nl reservoir solution from Swissci 96-well commercially available
screens (Molecular Dimensions). Crystals were obtained at 18 °C from a JCSG+
plate in a well solution (H6) of 0.1 M ammonium acetate, 17% (w/v) polyethylene
glycol 10,000, 0.1 M Bis-(2-hydroxyethyl)imino-tris(hydroxymethyl)methane pH
5.5. Crystals were cryoprotected by transfer into well solution augmented with 25%
(v/v) glycerol and cryocooled by transfer to liquid nitrogen.
Data were collected at the Diamond Light Source on beamline I03 and crystals
diffracting to 2.70 Å were used for structure determination and processed using
XDS56 and Aimless from the CCP4 suite57. Molecular replacement was performed
using Phaser58 with a truncated version of the crystal structure of TcHpHbR (PDB
4E40) as an alanine search model. This process placed two copies of the FHR in the
asymmetric unit. After initial building by hand in Coot59 and refinement in
BUSTER60, clear density was present for bovine FH domain 5 near the N terminus
of both copies of the FHR in the asymmetric unit, allowing subsequent rounds of
model building in Coot and refinement in BUSTER. Generation of a model of FHR
with FH and C3b was performed in Coot.
T. brucei PCF cell culture. T. brucei PCF strain J1061 was cultured in supple-
mented differentiating Trypanosome medium62 containing 10% (v/v) heat-
inactivated fetal calf serum (HI FCS) and 6.4 μg/ml haemin. Penicillin (86 U/ml)
and streptomycin (86 μg/ml) were also added. Cells were maintained in suspension
culture at 27 °C in a humidified incubator with 5% CO2 between 1 × 106 and 1 ×
107 cells/ml, and all experiments and transfections were performed when the cells
were in mid-log phase growth of 3–8 × 106 cells/ml.
Generation and confirmation of PCF FHR−/− cell lines. A strategy using long
oligonucleotide primers was used to delete the gene for the FHR on both alleles in
PCFs63. In brief, forward primers contained 80 base pairs upstream of the start
codon of the FHR gene and 20 base pairs upstream of the start codon for a
blasticidin or neomycin (G418) resistance gene. Reverse primers contained the last
20 base pairs of the resistance gene including the stop codon and around 80 base
pairs downstream of the stop codon of the FHR gene. The gene flanking sequences
were obtained from the TREU 927 reference genome49. PCR products were
introduced into PCF T. brucei by standard transfection procedure64 and trans-
formants were selected with 10 μg/ml of blasticidin and 45 μg/ml of neomycin.
To confirm deletion of the FHR gene, genomic DNA was extracted from WT
and suspected FHR knockouts. Genomic DNA (1 μg) was digested with NdeI and
NcoI followed by a Southern blot analysis and standard methods. DNA probes
prepared by PCR covered the entire FHR ORF of 816 base pairs with 5′-ATGAT
GATTTCCCGCGCTTTG and 5′-GAAAGAGAGGGCCGTGGCGGC-3′ or a
region 3′ of the ORF of 1023 base pairs with 5′-GCTCGCAGCTAATGATGATCC
and 5′-CGTGATGCCACGAGTCCCTTC-3′.
Tsetse fly infections with PCFs from an in vitro culture. Male and female tsetse
flies, Glossina morsitans morsitans and Glossina pallidipes, were infected with WT
and three independent FHR−/− clones as PCFs from culture61. Tsetse flies were
maintained on washed horse red blood cells61 and thus in the absence of active
complement. Infection of the midgut was assessed by dissection after 6 days.
Infections were scored as positive if live PCFs were observed on microscopic
examination65. As both WT and FHR−/− infections were observed, flies were
maintained for 28 days to allow progression to the salivary glands (see below). For
immunofluorescence assays, female G. pallidipes flies were infected with WT and
one FHR−/− clone, and were maintained in the same manner as describe above,
and the midgut (day 3) and midgut and proventriculus (day 10) were dissected and
subjected to immunofluorescence assays for determination of FHR expression.
Generation and maintenance of BSF FHR−/− cell lines. Infected salivary glands
from tsetse flies with WT and two FHR−/− clones were used to infect BALB/c
mice61. The experiments designed for this study were carried out according to the
UK Animals (Scientific) Procedures Act under a licence (30/3046) from the UK
Home Office and approved by the University of Bristol ethics committee. To adapt
BSFs to culture, aliquots of infected mouse blood were transferred into modified
HMI-11 media66 with 1% (w/v) methylcellulose, 10% HI FCS67 and cultured at 37 °
C with 5% CO2. Cells were maintained between 1 × 105 to 1 × 106 cells/ml and all
experiments were performed when the cells were in mid-log phase growth of 5 ×
105 to 1 × 106 cells/ml. BSF cells were adapted to standard culture by twofold
dilution every 2–3 days or more regularly as necessary, along with an incremental
decrease in methylcellulose.
The induction of stumpy BSFs in culture was performed by following an
established protocol42,43; 8-(4-Chlorophenylthio)adenosine 3′,5′-cyclic
monophosphate sodium salt (pCPT-cAMP, Sigma) was added to cultured slender
BSFs (100 μM) and cells were collected or analysed 24 h later.
Live-cell-binding assays with FH and moAb. PCFs were incubated in culture
with 100 nM of fluorescently labelled FH purified from bovine serum (see above) or
moAb raised against the FHR by phage display (AstraZeneca)68,69. In brief, phage
display selection strategy involved panning selections with biotinylated FHR on
streptavidin-coated plates or with unlabelled FHR on MaxiSorp plates, and soluble
selections with biotinylated FHR on magnetic streptavidin-coated Dynabeads.
GST-tagged and -untagged FHRs (see above) were used throughout and were
either left as is or biotinylated. When a GST-tagged protein was used, a GST de-
selection step was performed as a control. In all selections, 1 × 1012 phage particles
were incubated with immobilized FHR, followed by extensive wash steps (PBS or
with 0.1% Tween-20), de-selections (e.g., removal of non-antigen-binding phage-
scFv by pre-incubation with beads) and elution of bound phage with trypsin69.
E. coli TG1 were infected with eluted phage, followed by rescue with super-
infection of M13 KO7 helper phage. These phage were used for one to two further
rounds of selection. The enriched anti-FHR phage-scFv outputs were sequenced
to assess diversity and then tested further for FHR binding using phage enzyme-
linked immunosorbent assay. Bovine serum albumin and GST were negative
control antigens and phage displaying a negative control scFv. Binding of phage-
scFv was assessed with an anti-M13 HRP-conjugated antibody. Ten unique
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phage-scFv were obtained as soluble fragments in periplasmic extracts68 and were
selected for further binding analysis, and ranked using homogeneous time-
resolved fluorescence and BioLayer Interferometry on an Octet RED384 by
standard procedures. Nine purified anti-FHR scFv were selected, which bound
unique epitopes and converted into full-length human IgG1 using standard
techniques. Secreted antibodies were purified using protein A affinity
chromatography and labelled using an AlexaFluor 594 NHS ester labelling kit
(ThermoFisher)69. After 2 h of incubation, live cells were fixed in 1%
formaldehyde for 10 min. The cells were washed, resuspended in PBS and loaded
onto poly-lysine slides for visualization by microscopy. All nine anti-FHR moAbs
were tested and one is shown in this work.
Mouse infections with BSFs. Stabilates of infected mouse blood with T. brucei
BSF J10 WT and two FHR−/− clones were thawed and passaged via intraperitoneal
injection into immunosuppressed (Endoxan 300 mg/kg) BALB/c mice (BALB/cByJ,
Charles River)65. Immunosuppression was performed on the day of inoculation.
On day 3 post infection, blood from infected mice was diluted in PSG and was
injected into a further set of immunosuppressed BALB/c mice (5 × 106 cells per
mouse, 5 mice per cell line). On day 4 post infection, blood from infected mice was
diluted in phosphate buffered saline glucose (PSG) and injected into a further set of
immunocompetent BALB/c mice (1 × 106 cells per mouse, 5 mice per cell line).
Parasitaemia was monitored by microscopy of whole blood70. All mice were female
and age-matched. The experiments designed for this study were approved by the
regional Ethic Committee for Animal Experimentation CEEA-LR 36 under project
number 2018012915201897v2 and authorized by MENESR (French Ministry for
Higher Education and Research).
Mathematical modelling of BSF infections in mice. Mathematical modelling of
T. brucei infection dynamics in immunocompetent mice45,46 has been performed
here with minor modification. The model, as first described46, was fitted to the
parasitaemia of individual immunocompetent mice in this study, but the number
of antigenic variants was limited to three and a variant 3-induced immune response
was removed. PAD1 expression and slender, intermediate and stumpy cell pro-
portions were not measured and therefore not fitted. However, the dynamics of
slender and stumpy forms were modelled. The full details of the model are available
in Supplementary Data 1.
Tsetse fly infections with BSFs from infected mice. Female Glossina palpalis
gambiensis were fed on the bellies of infected, anaesthetized mice65 and subse-
quently on sheep blood by in vitro membrane feeding. Feeding on mice was
performed seven times and each time parasitaemia was matched closely (less than
twofold difference). The midguts from starved tsetse flies were dissected from 6 to
16 days post infection. Midgut infections were scored as positive if live PCFs were
observed on microscopic examination65. The experiments designed for this study
were approved by the regional Ethic Committee for Animal Experimentation
CEEA-LR 36 under project number 2018012915201897v2 and authorized by
MENESR (French Ministry for Higher Education and Research).
Immunofluorescence assays. WT and FHR−/− BSF cells were diluted to 1 × 105
cells/ml or 4 × 105 cells/ml+ pCPT-cAMP as described above. After 24 h, 1 × 107
cells were collected and washed with serum-free HMI-11, with or without pCPT-
cAMP. After resuspension in Voorheis-modified PBS (vPBS= PBS supplemented
with 46 mM sucrose, 10 mM glucose pH 7.6), cells were fixed for 30 min by adding
an equal volume of 8% paraformaldehyde. After dilution with vPBS, cells were
collected by centrifugation and settled onto poly-lysine slides in vPBS. Slides were
washed with vPBS, 10 mM ethanolamine pH 8 in vPBS, vPBS ± 0.1 % Triton X-100
and vPBS44. After blocking for 1 h in 5% donkey serum in vPBS, slides were
incubated with primary antibody for 1 h and then washed with vPBS44. Slides were
then incubated with secondary antibody for 1 h and washed again44. Slides were
incubated with Hoechst 33258 (0.1 mg/ml) for 5 min, washed and mounted with
FluorSave reagent44. The primary antibody used here was rabbit FHR antiserum
described above (1 : 200, 1 : 400 and 1 : 800 dilutions) and secondary antibody was
donkey anti-rabbit AlexaFluor 488 (1 : 1000 dilution). Microscopy was performed
using a Zeiss Axioimager M1; images were recorded using the Axiovision software
(Zeiss) and the same settings were used for all samples within a set of experiments.
Images were imported into Adobe Photoshop for figure preparation. The midgut
and proventriculus from tsetse flies infected with WT and FHR−/− PCF cells as
described above were dissected61. The organs were transferred directly to slides in
vPBS and fixed in an equal volume of 4% or 8% paraformaldehyde. The remaining
steps of the IFA were as described for cultured BSF cells.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The Source Data file contains the source data underlying all the figures as stated. The
crystal structure has been deposited in the Protein Data Bank (PDB ID 6XZ6) and all
other data are available from the authors on request. Correspondence and requests for
materials should be addressed to M.K.H. (matthew.higgins@bioch.ox.ac.uk) and M.C.
(mc115@cam.ac.uk).
Code availability
The code for the mathematical model in this work is deposited in GitHub and the links
and detailed description of the model can be found in Supplementary Data 1.
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